Dec 2, 2026
Grand Hi-Lai Hotel Taipei, Platinum Grand Ballroom B, Taipei, Taiwan
Driving Innovation, Investing in the Future
[The forum is co-organized by the RBMP, IBMI, and Everbright Biofund.]
What You’ll Gain:
MedTex is where global investors and startups converge each year. As Asia’s leading gateway to health-tech innovation, it connects capital, innovation, and future opportunities.
Investment Foresight
Stay ahead with exclusive insights from world-leading VCs, and capture the next wave of healthcare investment trends
Global Capital Connections
Forge partnerships with international investors, corporates, and strategic collaborators to unlock global opportunities
Deal Flow Access
Spot the next generation of breakthrough startups backed in healthcare and biotech sectors.
What You Need to Know
This Event is Invitation Only
To ensure the quality of the forum and proper seating arrangements, participation is by invitation only.
Available till November 18
As seats are limited, please complete your registration by November 18 to secure your seat.
If you would like to recommend investors or industry leaders to attend, please contact:
Dr. Jim Shih | +886-2-2655-7888 Ext.632 | jim@rbmp.org.tw
The summit provides real-time AI translation.
Event Agenda
-
10:0010:10Opening
Opening Remarks
- Pan-Chyr YangPresident, IBMI; Board Member, RBMP; Board Member, Everbright Biofund
-
10:1010:20Opening
Everbright Biofund: Investing in Healthcare, Partnering for Global Growth
- Charles LinManaging Director, Everbright Biofund
-
10:2010:40Keynote
The Future of HealthTech
- Yael Gruenbaum-CohenFounder & General Partner, Entrée Bio
-
10:4011:00Keynote
The New Capital Cycle: Investing Where AI Meets Life Sciences
- Shaq VaydaPartner, Lux Capital
-
11:0012:00Pitch I
Pitch Session IAI-Driven Drug Discovery & Development
Chair
- Pan-Chyr YangPresident, IBMI; Board Member, RBMP; Board Member, Everbright Biofund
Speakers
- EnvedaJason Kim, CFO
- MetaphoreAngela Hwang, CEO
- Algen BiotechnologiesChun-Hao Huang, Co-Founder & CEO
- AION LabsMati Gill, CEO
Investor Q&A and Investment Perspectives Session Chair, Everbright Biofund Investment Team and invited international VC investors -
12:0013:10Break
Networking Lunch
-
Roundtable
Global VC RoundtableWhere Capital Goes Next: Global Healthcare Investment Outlook for 2027
13:1013:20Featured Insight
- Matt BettonvilleInvestor, Yosemite Venture Fund
13:2014:30Panel Discussion
Moderator
- Charles LinManaging Director, Everbright Biofund
Panelists
- Matt BettonvilleInvestor, Yosemite Venture Fund
- Markus KalousekVenture Partner, BioGeneration Ventures
- Ian ChiangPartner, Flare Capital Partners
- Jonathan WangVice President, Ally Bridge Group
-
14:3015:30Pitch II
Pitch Session IINext-Generation Therapeutics & Drug Delivery
Chair
- Pan-Chyr YangPresident, IBMI; Board Member, RBMP; Board Member, Everbright Biofund
Speakers
- Mana.bioYogev Debbi, CEO
- ImmunoScapeMichael Fehlings, Co-Founder & CTO
- Marigold TherapeuticsMei-Hsuan (Maggie) Tsai, CSO
- Onward TherapeuticsGrace Yeh, Chairperson & CEO
Investor Q&A and Investment Perspectives Session Chair, Everbright Biofund Investment Team and invited international VC investors -
15:3016:00Break
Coffee & Networking Break
-
16:0017:00Pitch III
Pitch Session IIIPrecision Medicine & Innovative Medical Technologies
Chair
- Chung-Liang ChienCEO, IBMI
Speakers
- Atropos HealthBrigham Hyde, Co-Founder & CEO
- BioPro ScientificHsin Chen, Founder & CEO
- EndiatxTorrey Smith, Co-Founder
- Reconnect LabsDario Dornbierer, Co-Founder & CSO (pre-recorded)
Investor Q&A and Investment Perspectives Session Chair, Everbright Biofund Investment Team and invited international VC investors -
17:00Networking
Investor & Innovator Networking
Yael Gruenbaum-Cohen
Founder and General Partner
Dr. Yael Gruenbaum-Cohen is Founder and General Partner of Entrée Bio, with nearly two decades of experience in healthcare, biotech, and venture investing. Previously a Partner at aMoon and General Manager at Medison Ventures, she has led investments, pharmaceutical partnerships, and commercialization initiatives. She holds a DMD and PhD in molecular genetics and co-founded Andlit Therapeutics and WE@HealthTech, an initiative advancing female leadership in health technology.
Shaq Vayda
Partner
Shaq is a partner at Lux. He is drawn to instruments that make the invisible legible – a theme that guided him from early DSP work at NASA and Northrop Grumman, where he helped process infrared and RF data for missions including the James Webb Space Telescope, to decoding genomic signal at Illumina and supporting GRAIL’s liquid-biopsy platform from its earliest days. That technical background – spanning physical sciences, life sciences, and computational sciences – shapes how he partners with founders who are looking where no one else is. He invests in platform and “building block” companies where the downstream value created is greater than that of the company itself, and is at his best working with deeply technical teams from inception.
At Lux, which has over $7 billion under management, he sits across a platform that has been first investors in category-defining companies spanning AI, automation, biotech, compute, defense, energy, infrastructure, robotics, and beyond – from Anduril, Applied Intuition, Erebor, and Physical Intelligence in the built world, to Auris and Enveda in human health, to Cognition, Databricks, Ramp, and Runway in AI and software infrastructure, among many others. The firm has created and cofounded more than 20 de novo companies through Lux Labs, and multiple Lux investments have become lasting public companies and significant acquisitions by Amazon, Cisco, Databricks, J&J, Meta, Palo Alto Networks, and more.
Shaq grew up on the Space Coast of Florida and earned his Bachelor’s in Mechanical Engineering from the University of Florida. Before Lux, he advised mega-cap private equity investors on enterprise technology and healthcare investments at Parthenon. He built a high-altitude balloon spacecraft in high school to photograph the curvature of Earth and remains passionate about living up to his name and finally dunking a basketball. An avid Gators fan, he can otherwise be found searching for the greatest bagel in the Bay Area.
Matt Bettonville
Investor
Matt Bettonville is an investor at Yosemite, where he leads healthcare investment strategy. Previously, he led healthcare venture investments at Emerson Collective and worked as a software engineer at Apple, contributing to the development of AirPods and Continuity features. He holds a B.S. in Computer Science from Stanford University and serves on the boards of multiple healthcare technology companies, focusing on AI, digital health, and healthcare innovation.
Markus Kalousek
Venture Partner
Markus Kalousek, PhD, is a biotech entrepreneur, venture capital investor, and board chairman with over 26 years of pharmaceutical industry experience. Previously a senior leader at Novartis, he has led drug development, strategic partnerships, and external innovation across multiple therapeutic areas. He currently serves as Venture Partner at Biogeneration Ventures and holds leadership roles in several biotech startups, specializing in company creation, investment strategy, and translating scientific innovation into patient impact.
Jonathan Wang
Vice President
Jonathan Wang is a Vice President at Ally Bridge Group, where he focuses on investments in the biotech sector. He previously served as an Investment Manager at Navis Capital Partners, evaluating and executing private equity investments across Asia. He began his career in transaction services at PricewaterhouseCoopers. He holds an MPhil in Biochemistry from the University of Hong Kong and a BSc in Applied Biology and Biotechnology from The Hong Kong Polytechnic University.
Ian Chiang
Partner
Ian Chiang is a Partner at Flare Capital Partners, where he leads investments in healthcare technology companies, including Isaac Health, Knownwell, Peer AI, and Rx Redefined. He also oversees early-stage investments through Flare Scholar Ventures, supporting innovative startups across healthcare and education.
Prior to Flare Capital, Ian was a founding team member and Senior Vice President at CareAllies, a Cigna healthcare services venture. He co-founded Scanwell Health, a smartphone-based diagnostics company acquired by BD in 2021, and previously led product innovation at BD and advised global healthcare clients at McKinsey & Company. He holds a BS in Biological Engineering from Cornell University and an MBA from Harvard Business School.
VCs (Venture Capitalists)
Top venture capitalists specializing in AI, digital health, and biotech converge to share actionable insights and redefine healthcare investment strategies.
Pitch Sessions
Cutting-edge startups from AI, digital health, and biotech converge to unveil the technologies redefining
Mati Gill
CEO & Founder
Jason Kim
CFO
Angela Hwang
CEO-Partner & CEO
Michael Fehlings, PhD
Co-founder & CTO
Chun-Hao Huang
Co-Founder & CEO
Yogev Debbi
Co-founder & CEO
Hsin Chen
CEO
Brigham Hyde
Co-founder & CEO
Torrey Smith
Co-Founder & Engineering Fellow
Davor Kosanic
Co-Founder & CEO
Mei-Hsuan Tsai
CSO
Grace Yeh
Co-Founder & CEO
Mati Gill
CEO and Founder
Mati Gill is CEO and Founder of AION Labs, a venture studio with a first-of-its-kind company creation model for new biotech and deeptech start-ups utilizing AI for drug discovery and development. AION Labs is a unique alliance of Pfizer, Amazon Web Services, AstraZeneca, Teva, Merck KGaA, the Israel Biotech Fund, Amiti Ventures and Entrée Bio supported by the Israel Innovation Authority (IIA).
Prior to founding AION Labs, Mati was a senior executive at Teva and served as Chief of Staff for in the Israeli Cabinet. He Chairs the Israel Export Institute Healthcare and Lifesciences Division and serves on the boards of the Israel Advanced Technology Industries Association (IATI) and the Israel America Chamber of Commerce (AmCham).
Jason Kim
Chief Financial Officer
Jason brings over 20 years of extensive biopharmaceutical corporate development and financial leadership to Enveda, where he oversees financial strategy, business development and operations. Prior to joining Enveda, Jason served as President, COO, and CFO of Molecular Templates, leading business development, finance, and operations. He played a pivotal role in securing over half a billion in equity, strategic partnerships, and non-dilutive funding, while guiding the company through its successful transition to a public entity. He established partnerships with top pharma companies Takeda, Vertex, and Bristol Myers Squibb. He also held leadership roles at ImClone Systems, OSI Pharmaceuticals, Domain Associates, and Safeguard Scientifics. Jason earned an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.
Angela Hwang
CEO-Partner and CEO
Angela Hwang joined Flagship Pioneering in 2025 as CEO-Partner and CEO of Metaphore Biotechnologies. Angela brings three decades of experience at Pfizer, where she held senior leadership roles, including most recently as a member of Pfizer’s executive leadership team, serving as Chief Commercial Officer and President of the Global Biopharmaceuticals
Business. Angela’s teams brought nearly 600 critical therapies in oncology, internal medicine, rare diseases, inflammation and immunology, vaccines and hospital injectables to patients across 185 countries. She has led many groundbreaking product launches during her career, including the world’s first COVID-19 vaccine and oral antiviral treatment, and executed dozens of business development deals to grow and expand Pfizer’s portfolio.
Angela currently serves on the Board of Directors of UPS. She is also a member of the Board of Trustees of Cornell University and a board member of Apriori Bio, an innovative vaccines company.
Consistently recognized for her leadership, she has been ranked among the world’s top leaders in healthcare and business. Angela was named to Fierce Pharma’s Fierce 50 list in 2025 and selected by CNBC as a Changemaker in Business in 2024. In 2023, she was recognized as an Ascend A-List Honoree for her professional achievements as an Asian American leader.
Fortune named her as one of The Most Powerful Women in Business four years in a row from
2020 to 2023. Cornell University named her a Robert S. Hatfield Economic Fellow in 2022. In 2021, she received The President’s Award from the National Diversity Council and was also named an A100 Honoree, which recognizes the most impactful AAPI leaders.
Angela received a B.S. in Microbiology from the University of Cape Town and an MBA from Cornell University.
Michael Fehlings, PhD
Co-founder & CTO
Michael Fehlings, PhD, is Co-founder and CTO of ImmunoScape, a biotechnology company pioneering next-generation T cell therapies designed for long-term efficacy against solid tumors. He leads the company’s innovation and scientific strategy and built ImmunoScape’s Seed-and-Boost platform, translating advances in T cell biology into cancer therapeutics.
Prior to ImmunoScape, he led research at the Singapore Immunology Network (A*STAR), spearheading efforts to identify and characterize antigen-specific T cells in cancer and infectious disease.
He holds a PhD in Immunology from Humboldt University of Berlin, Germany, and has authored over 30 peer-reviewed publications in immunology and cancer immunotherapy.
Chun-Hao Huang, Ph.D.
Co-Founder & CEO
Dr. Huang co-founded Algen Bio, serves as the CEO with the mission to revolutionize therapeutic drug discovery through advanced CRISPR gene-modulation and frontier AI. A genetic engineer, drug developer and AI entrepreneur, he received postdoctoral fellow at UC Berkeley under Nobel Laureate Professor Jennifer Doudna, and Ph.D. at MSKCC/Weill Cornell Medicine under HHMI Professor Scott Lowe. Dr. Huang pioneered disease-relevant models using CRISPR, which led to the discovery of new therapeutic strategies for treating cancer and inflammatory diseases. He also applied machine learning to the study of gene functions and invented methods to identify biomarkers that predict drug responses. Dr. Huang’s accolades include an Edison Award, TIME Best Inventions of 2026, and being named a Lindau Nobel Laureate Meeting Fellow, UN’s UNLEASH Sustainable Development Goals Talent, MIT Technology Review’s Innovators Under 35, and LA Times’ Life Sciences Visionary.
Yogev Debbi
Co-founder and CEO
Yogev Debbi is the Co-founder and CEO of Mana.bio, a biotechnology startup leveraging AI to develop programmable delivery solutions for RNA therapies. He brings a proven track record of scaling high-growth companies, having served as VP of Strategic Projects at monday.com during its IPO readiness and as General Manager at Twist Bioscience following its acquisition of Genome Compiler, a synthetic biology platform he co-founded. Earlier in his career, he held key technical management roles at Intel Corporation. He holds a Global MBA in Innovation & Entrepreneurship and a B.A. in Computer Science, Summa Cum Laude, from the Interdisciplinary Center (IDC), Herzliya.
Dr. Hsin Chen CEO
CEO
Dr. Hsin Chen is the Founder and Chief Executive Officer of BioPro Scientific, leading the company’s growth and strategic direction since its inception in 2018. He concurrently serves as a Professor in the Department of Electrical Engineering and the Institute of Electronics Engineering at National Tsing Hua University (NTHU), while also acting as an industry advisor in medical technology and biomedical microchips. Prior to founding BioPro Scientific, Dr. Chen dedicated his academic career to pioneering interdisciplinary research in brain-computer interfaces (BCIs), biomedical integrated circuits (ICs), and neuromorphic hardware design. He has also served as a visiting professor at the IMS Laboratory at the University of Bordeaux and the IBISC Laboratory at the University of Évry in France, promoting international academic collaboration in biomedical engineering.
Dr. Chen holds a Ph.D. in Electrical and Electronic Engineering from the University of Edinburgh. His distinguished achievements have been recognized with numerous accolades, including the National Innovation Award, the Outstanding Young Scholar Award from the Taiwan IC Design Society (TICD), and the Best Advisor Award at the Macronix Golden Silicon Awards. Specializing in advanced bidirectional brain-computer interfaces and edge AI chip technologies, Dr. Chen has successfully translated academic research breakthroughs into globally competitive neurotechnology devices and integrated solutions, demonstrating exceptional contributions to biomedical chip entrepreneurship and neuroengineering innovation.
Dr. Brigham Hyde
Co-Founder & CEO
Dr. Brigham Hyde is CEO and co-founder of Atropos Health since 2022. He provided funding and support for Atropos Health’s official launch in late 2020. Hyde has a significant track record of building businesses in the health tech and real-world data (RWD) space and previously served as President of Data & Analytics at Eversana. Prior to that role, Hyde served as a healthcare partner at the AI venture fund Symphony AI, where he led the investment in, co-founded, and operated Concert AI, an oncology RWD company – valued at $1.9B. Hyde held previous roles as Chief Data Officer at Decision Resources Group, which was acquired by Clarivate for $900M in 2020. He has also served on the Global Data Science Advisory Board for Janssen, as a research faculty at MIT Media Lab, and served as adjunct faculty at Tufts Medical School.”
Torrey Smith
Co-Founder & Engineering Fellow
Torrey Smith is the Co-Founder & Engineering Fellow of Endiatx, a medical device company developing the first robots that live and work inside the human body, starting with the stomach. He is the primary visionary behind PillBot™, Endiatx’s investigational robotic endoscopic capsule designed to enable real-time visualization and navigation. His work at Endiatx is part of a broader vision to develop a new generation of miniature robotic technologies for diagnostic and, eventually, therapeutic applications inside the body.
Prior to founding Endiatx, Torrey developed medical devices that contributed to three successful exits, including the Mara™ Water Vapor Ablation system, acquired by CooperSurgical; the Phoenix Atherectomy™ System, acquired by Volcano Corporation and now part of Philips; and the EXOSEAL™ Vascular Closure Device, acquired by Cordis/J&J.
An aerospace engineer by training, Torrey has a longstanding interest in deep technology, robotics, and medical device innovation. He is a mentor at the Founder Institute and the principal founder of Sextant, an international arts collective. His design work has also been featured by the Smithsonian.
Davor Kosanic PhD.
Co-Founder & CEO
Davor Kosanic (PhD) is a serial entrepreneur and scientist with over 15 years of healthcare innovation expertise.
Davor is the CEO and co-founder of Reconnect Labs – a leading Swiss precision neuropsychiatry biotech company, and director of the Reconnect Foundation.
He previously co-founded and led the disruptive medical device company SamanTree Medical as CEO, and was promoting impact entrepreneurship and sustainability related innovation at the Vice-Presidency of Innovation at EPFL.
Dr. Grace Yeh
Co-Founder & CEO
Dr. Grace Yeh is a co-founder, CEO, and Chairperson of Onward Therapeutics SA, which she has led since its inception in 2019. She currently serves on the boards of Biomunex Pharmaceuticals SAS and Emercell SAS in France, and holds leadership positions at the Taiwan Bio Industry Organization and the Taiwan Women on Boards Association.
From 2003 to 2019, Dr. Yeh founded and led PharmaEngine, a publicly listed oncology company headquartered in Taipei, with a wholly owned subsidiary in Paris. Under her leadership, the company achieved a market capitalization exceeding US$1 billion in 2015. Its development portfolio includes two approved products, ONYVIDE® and HENSIFY®. Prior to returning to Taiwan, she held senior positions at Millennium Pharmaceuticals, LeukoSite, CytoMed, and T Cell Sciences in Cambridge, Massachusetts. She also conducted academic research at INSERM in France and the Blond McIndoe Centre for Transplantation Biology in the UK.
Dr. Yeh holds a PhD in Immunology from the Medical University of South Carolina. Her achievements include the Fu Jen Catholic University Outstanding Alumni Award (2015), the EY Entrepreneur of the Year Award (2016), and becoming the first female laureate of the Industrial Technology Research Institute in 2021.
Mei-Hsuan Tsai, PhD
CSO
Mei-Hsuan Maggie Tsai, PhD is currently Chief Scientific Officer at Marigold Therapeutics, where she focuses on innovation and drug development in antibody-drug conjugates (ADCs). She brings extensive experience in ADC research and development, having previously held leadership positions at BeOne, HitGen, and WuXi Biologics, including Director of ADC Development, Associate Director of DEL Technology, and Associate Director of Bioconjugation Development.
Dr. Tsai has led more than 20 ADC development programs, with five candidates advancing into clinical trials, including one currently in Phase III. She is the inventor on 32 ADC-related patents covering payloads, linkers, conjugation technologies, and ADC products. She holds a PhD in Chemistry from the University of Cambridge and was recognized with the Biocom Catalyst Award.
Organized by
RBMP
IBMI
Everbright Biofund
Supported by
MEDTEX Countdown
Dec 2, 2026 · 10:00 – 17:00
Contact Phone Number :
886-2-26559188
2026 Medtex
Past Events
Regulations
© EverRise Biomedical Co. Ltd. All rights reserved.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.